Global MicroRNA Market Overview
As per MRFR analysis, the MicroRNA Market Size was estimated at 1.05 (USD Billion) in 2023. The MicroRNA Market is expected to grow from 1.16 (USD Billion) in 2024 to 3.5 (USD Billion) by 2035. The MicroRNA Market CAGR (growth rate) is expected to be around 10.56% during the forecast period (2025 - 2035)
Key MicroRNA Market Trends Highlighted
Increased research in molecular biology and genomics, which are essential for the creation of tailored medicines, is propelling the MicroRNA Market's notable developments. One of the main factors propelling the market is the increasing understanding of how microRNAs control gene expression and their possible use in customized treatment.
Innovation in clinical research and the creation of microRNA-based diagnostics and treatments are also encouraged by growing investments in healthcare infrastructure across different countries. As players investigate innovative uses of microRNAs in the management and treatment of cancer, opportunities abound in the global market.
Growing investigations into the function of microRNAs in different illnesses have created new opportunities for pharmaceutical development. This is becoming more and more crucial as cutting-edge technologies like CRISPR and other gene-editing techniques combine with microRNA applications, providing a wide range of possibilities for revolutionary treatments.
Current patterns show that academic institutions and biotech businesses are increasingly working together to develop therapies linked to microRNA, which will increase the ecosystem's potential for innovation. Additionally, developments in bioinformatics and data analytics are generating new understandings of microRNA functions, opening the door to tailored treatment strategies.
Additionally, there is a discernible trend toward regulatory approvals for goods based on microRNA, confirming their importance in global health solutions. The MicroRNA Market is expected to change as a result of growing acceptance and knowledge of innovative treatments, offering a dynamic array of opportunities for better patient outcomes.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
MicroRNA Market Drivers
Increasing Incidence of Cancer Worldwide
The rising number of cancer patients on a global scale has emerged as a significant driver for growth in the MicroRNA Market. According to the World Health Organization (WHO), global cancer incidence rates are projected to rise by 47% from 2020 to 2040, leading to approximately 29.5 million new cases annually by 2040.
This alarming trend highlights the urgent need for innovative therapeutic approaches, including microRNA-based therapies that are being researched and developed by leading organizations such as the National Institutes of Health (NIH) and the American Cancer Society.
With the global health systems increasingly focused on personalized medicine, advancements in microRNA technology are vital in developing targeted cancer treatments, thereby driving demand in the MicroRNA Market. The surge in funding for research and development in this domain supports this trend, as governments and private sector stakeholders unite in the fight against cancer.
Growing Investment in Research and Development
There is a notable increase in investment in Research and Development within the MicroRNA Market, underpinning market growth. The global spending on healthcare R&D reached approximately 2.4 trillion USD in 2020 and continues to rise as nations recognize the importance of biotech innovations.
Initiatives from government bodies and key organizations, such as the National Science Foundation (NSF) in the United States and research councils in Europe, are directing funds towards biotechnology and, specifically, microRNA research.This surge indicates a commitment to developing new diagnostic and therapeutic solutions that utilize microRNA technology, propelling market expansion in the forthcoming years.
Advancements in Diagnostic Techniques
Innovations in diagnostic techniques are propelling the growth of the MicroRNA Market. The development of microRNA-based diagnostic tools has demonstrated promise, particularly in early cancer detection. The global liquid biopsy market, which includes techniques that utilize microRNA profiling, is projected to reach about 9.5 billion USD by 2027, reflecting a compound annual growth rate of 23%.
This rapid growth is fueled by technological advancements being driven by organizations such as the Food and Drug Administration (FDA) and relevant healthcare associations, which support the validation of microRNA as potential biomarkers. These advancements underline the increasing importance of microRNA diagnostics, fostering demand in the MicroRNA Market.
MicroRNA Market Segment Insights
MicroRNA Market Application Insights
The Application segment of the MicroRNA Market was poised for substantial growth, driven by the increasing prevalence of various health conditions and the expanding recognition of microRNAs' role in disease management and diagnosis.The MicroRNA Market revenue reflected a strong alignment with significant applications such as Oncology, Cardiovascular Diseases, Neurological Disorders, and Infectious Diseases.
Notably, the Oncology application held a major share, valued at 0.5 USD Billion in 2024 and projected to reach 1.5 USD Billion by 2035. This remarkable increase highlighted the critical role of microRNAs in cancer biology, potentially facilitating early detection and targeted therapies, making it a priority area for investment and innovation.
The Cardiovascular Diseases application followed, estimated at 0.3 USD Billion in 2024, with growth expected to 0.9 USD Billion by 2035. This segment gained importance due to microRNAs' potential in regulating cardiovascular health and their involvement in various cardiovascular disorders, thereby meeting a crucial need in global healthcare.
Neurological Disorders, estimated at 0.2 USD Billion in 2024 and expanding to 0.7 USD Billion in 2035, emerged as an important application area as the understanding of microRNAs in neurogenesis, neuronal differentiation, and neurological disease progression becomes clearer.
Lastly, the Infectious Diseases application, while valued at 0.16 USD Billion in 2024 and growing to 0.4 USD Billion by 2035, illustrated the burgeoning interest in utilizing microRNAs as biomarkers and therapeutic targets for a variety of infections, reflecting a significant opportunity in the global market landscape.
Overall, the MicroRNA Market segmentation revealed a diverse range of applications, each holding significant potential for growth and innovation, driven by the pressing need for advanced diagnostic and therapeutic solutions globally.Understanding these dynamics was essential for stakeholders aiming to capitalize on the emerging trends in the MicroRNA Market, as each application offered unique challenges and opportunities that can transform patient outcomes and drive market growth.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
MicroRNA Market Product Type Insights
Within this market, various product types play a crucial role, including MicroRNA Mimics, MicroRNA Inhibitors, MicroRNA Isolation and Purification Kits, and MicroRNA Detection Kits. MicroRNA Mimics and Inhibitors are pivotal for their roles in gene regulation and therapeutic interventions, significantly impacting Research and Development activities.The Isolation and Purification Kits are in high demand due to their necessity in extracting microRNA from biological samples, essential for accurate analysis.
Detection Kits are equally important, facilitating the quantification of microRNA levels in research settings and clinical diagnostics. The overall market growth is further supported by the rising prevalence of chronic diseases and the growing emphasis on personalized medicine.
MicroRNA Market End-user Insights
The MicroRNA Market is poised for substantial growth, especially within the End-user segment, which comprises entities such as Research Laboratories, Pharmaceutical Companies, and Contract Research Organizations.Research Laboratories play a critical role in advancing MicroRNA research, providing essential data and insights that drive innovations. Pharmaceutical Companies leverage MicroRNA for drug development processes, enhancing therapeutic strategies and patient outcomes, which further amplifies their significance in the market landscape.
Contract Research Organizations facilitate a vital link between research and commercialization, offering specialized services that streamline the drug approval process. The growing trends in personalized medicine, along with increasing investments in research and development, are considerable growth drivers for this segment.The complexities faced by these End-users, such as the need for regulatory compliance and the high costs of R&D, present both challenges and opportunities. These dynamics are reflected in the MicroRNA Market statistics, which indicate robust growth driven by advancements across these distinct yet interconnected players in the industry.
MicroRNA Market Technology Insights
The MicroRNA Market within the Technology segment is robust and shows promising growth. The market is propelled by advanced methodologies in PCR Technologies, Sequencing Technologies, and Microarray Technologies, each playing a significant role in the detection and analysis of microRNAs.
PCR Technologies offer enhanced sensitivity and specificity, making them a preferred choice in laboratories for validating microRNA expression levels, while Sequencing Technologies advance the understanding of microRNA functions at the genomic level, driving significant innovations in personalized medicine.Microarray Technologies, on the other hand, facilitate the simultaneous analysis of thousands of microRNAs, supporting high-throughput screening which is critical for large-scale studies in genomics.
The overall market demonstrates a favorable trajectory supported by increasing research and development initiatives, rising healthcare expenditures, and an expanding focus on molecular diagnostics across the globe. Key trends indicate a growing demand for targeted therapies, emphasizing microRNA’s potential in disease management, particularly in oncology.However, challenges such as high investment costs and regulatory hurdles continue to pose obstacles. Overall, this sector represents a dynamic arena for expansion and innovation in the MicroRNA Market.
MicroRNA Market Regional Insights
The MicroRNA Market showcased notable growth across various regions, with North America leading the charge, holding a substantial market value of 0.56 USD Billion in 2024 and projected to elevate to 1.68 USD Billion by 2035. This dominated the market due to high investments in Research and Development and a strong healthcare infrastructure.
Europe followed closely, with a valuation of 0.38 USD Billion in 2024, expected to reach 1.14 USD Billion by 2035, driven by advanced biotechnology sectors and robust regulatory frameworks. In South America, the market was valued at 0.08 USD Billion in 2024, expanding to 0.25 USD Billion in 2035, as the region increasingly focuses on healthcare improvements.
The Asia Pacific region, valued at 0.12 USD Billion in 2024 and forecasted to escalate to 0.36 USD Billion by 2035, was significant due to its rapidly evolving medical research landscape. Meanwhile, the Middle East and Africa, with a market valuation of 0.02 USD Billion in 2024, expected to grow to 0.07 USD Billion by 2035, reflected the emerging interest in genetic research, despite facing infrastructure challenges.Such diverse regional dynamics contributed to the overall MicroRNA Market revenue, characterized by varied growth drivers influencing market trends, opportunities, and challenges across these regions.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
MicroRNA Market Key Players and Competitive Insights
The MicroRNA Market has emerged as a significant segment within the biotechnology field, driven by the increasing recognition of the role microRNA plays in gene regulation and its potential implications in various diseases.As the market continues to evolve, competitive insights reveal a dynamic landscape characterized by innovation, strategic partnerships, and robust research and development initiatives. Companies operating within this sphere are leveraging advanced technologies to develop novel microRNA-based therapeutics and diagnostic tools, thereby enhancing their offerings and expanding their market reach.
The rising demand for personalized medicine, along with increased funding for research related to microRNA, has further intensified competition, positioning key players to capitalize on emerging opportunities and respond to evolving consumer and healthcare needs.Thermo Fisher Scientific stands out in the MicroRNA Market due to its extensive portfolio of products and services dedicated to microRNA research and applications. The company has established a strong market presence by delivering high-quality reagents, assays, and platforms designed to facilitate the study and manipulation of microRNA.The strengths of Thermo Fisher Scientific lie in its commitment to innovation, leading-edge technology development, and comprehensive customer support services.
Its robust global distribution network enables the company to reach a diverse clientele, ranging from academic researchers to large pharmaceutical firms, all of whom seek reliable solutions for their microRNA-related studies and applications. This strategic placement fosters the company's competitive edge in the ever-evolving landscape of microRNA technologies.Biocept has carved a niche for itself within the MicroRNA Market, focusing primarily on liquid biopsy solutions that harness the power of microRNA for cancer diagnostics and monitoring. The company’s key offerings include proprietary technologies that enable the detection and analysis of circulating microRNA, which serves as valuable biomarkers for various cancers.
Biocept's strengths lie in its innovative approach to biomarker discovery and its ability to provide accurate, non-invasive diagnostic options. The company has made headlines with strategic mergers and acquisitions that enhance its technological capabilities and market footprint.Through these initiatives, Biocept expands its global reach and solidifies its position in the highly competitive microRNA landscape, catering to the needs of clinicians and patients alike. The emphasis on research collaboration and partnership further bolsters the company’s standing within the MicroRNA Market, enabling it to remain at the forefront of advancements in this rapidly growing sector.
Key Companies in the MicroRNA Market Include
- Thermo Fisher Scientific
- Biocept
- Agilent Technologies
- DnaGenotech
- Horizon Discovery
- Integrated DNA Technologies
- Genomatix
- Asuragen
- NantHealth
- Qiagen
- SigmaAldrich
- Roche
- ArcherDX
- Illumina
- Exiqon
MicroRNA Market Developments
Between 2025 and 2026, Qiagen plans to introduce three new sample-preparation tools—QIAsymphony Connect, QIAsprint Connect, and QIAmini—to improve automated workflows for nucleic acid extraction, including microRNA, and serve both high-throughput and low-throughput labs with increased sustainability, efficiency, and digital integration. This announcement was made on April 15, 2025.
With the release of their QIAseq Multimodal DNA/RNA Library Kit on May 29, 2024, Qiagen made it possible to prepare DNA and RNA libraries from a single sample simultaneously, allowing multiomic research and providing efficient support for miRNA sequencing operations.Novartis signed a deal to buy Regulus Therapeutics, a clinical-stage biotech business located in San Diego that specializes in creating first-in-class microRNA-targeted treatments for a range of disease areas, "last month" (April 2025).
Following preclinical findings showing total eradication of distant metastases in up to 65% of animal models, TransCode Therapeutics recently announced that their main product, TTX-MC138 targeting miR-10b for metastatic breast cancer, successfully began a phase 0 human trial in 2023.
Furthermore, Arcturus Therapeutics, a company that creates lipid-nanoparticle RNA medications that include microRNA modalities, keeps improving its platform, which has lately gained recognition for its adaptability in siRNA, mRNA, antisense oligonucleotides, and microRNA drug delivery.
Thermo Fisher Scientific has also highlighted how its Applied Biosystems platforms, including as SOLiD sequencing systems and TaqMan assays, enhance researcher skills in miRNA discovery and quantification by providing complete miRNA workflow support, from isolation to profiling and validation.
MicroRNA Market Segmentation Insights
MicroRNA Market Application Outlook
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Diseases
MicroRNA Market Product Type Outlook
- MicroRNA Mimics
- MicroRNA Inhibitors
- MicroRNA Isolation and Purification Kits
- MicroRNA Detection Kits
MicroRNA Market End-user Outlook
- Research Laboratories
- Pharmaceutical Companies
- Contract Research Organizations
MicroRNA Market Technology Outlook
- PCR Technologies
- Sequencing Technologies
- Microarray Technologies
MicroRNA Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
|
Report Attribute/Metric
|
Details
|
|
Market Size 2023
|
1.05(USD Billion)
|
|
Market Size 2024
|
1.16(USD Billion)
|
|
Market Size 2035
|
3.5(USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
10.56% (2025 - 2035)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2024
|
|
Market Forecast Period
|
2025 - 2035
|
|
Historical Data
|
2019 - 2024
|
|
Market Forecast Units
|
USD Billion
|
|
Key Companies Profiled
|
Thermo Fisher Scientific, Biocept, Agilent Technologies, DnaGenotech, Horizon Discovery, Integrated DNA Technologies, Genomatix, Asuragen, NantHealth, Qiagen, SigmaAldrich, Roche, ArcherDX, Illumina, Exiqon
|
|
Segments Covered
|
Application, Product Type, End-user, Technology, Regional
|
|
Key Market Opportunities
|
Increasing prevalence of cancer, Growth in personalized medicine, Advances in diagnostic technologies, Expanding applications in therapeutics, Rising research funding and investments
|
|
Key Market Dynamics
|
Increasing prevalence of chronic diseases, Growing applications in diagnostics, Advancements in research technologies, Rising investment in biotechnology, Expanding therapeutic applications
|
|
Countries Covered
|
North America, Europe, APAC, South America, MEA
|
Frequently Asked Questions (FAQ) :
The MicroRNA Market was valued at 1.16 billion USD in 2024.
By 2035, the MicroRNA Market is projected to reach a value of around 3.5 billion USD.
The expected CAGR for the MicroRNA Market from 2025 to 2035 is 10.56%.
North America held the largest market share, valued at 0.56 billion USD in 2024.
The Oncology application segment is anticipated to reach a market size of about 1.5 billion USD by 2035.
Major players in the market include Thermo Fisher Scientific, Biocept, Agilent Technologies, and Illumina, among others.
The Cardiovascular Diseases application segment is expected to be valued at approximately 0.9 billion USD by 2035.
The Asia Pacific region is expected to grow from 0.12 billion USD in 2024 to about 0.36 billion USD by 2035.
In 2024, the market size for the Infectious Diseases application was around 0.16 billion USD.
The market size for the Middle East and Africa is projected to reach about 0.07 billion USD by 2035.
